Free Trial

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics logo
$14.82 -1.16 (-7.26%)
Closing price 04:00 PM Eastern
Extended Trading
$15.09 +0.27 (+1.82%)
As of 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiNK Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
1
Buy
3

Based on 5 Wall Street analysts who have issued ratings for MiNK Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a sell rating, 1 has given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for INKT.

Consensus Price Target

$37.50
153.04% Upside
According to the 5 analysts' twelve-month price targets for MiNK Therapeutics, the average price target is $37.50. The highest price target for INKT is $40.00, while the lowest price target for INKT is $35.00. The average price target represents a forecasted upside of 153.04% from the current price of $14.82.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for INKT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MiNK Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INKT Analyst Ratings Over Time

TypeCurrent Forecast
8/28/24 to 8/28/25
1 Month Ago
7/29/24 to 7/29/25
3 Months Ago
5/30/24 to 5/30/25
1 Year Ago
8/29/23 to 8/28/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.50$37.50$37.50$90.00
Forecasted Upside153.04% Upside124.55% Upside437.25% Upside1,032.22% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy

INKT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

INKT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MiNK Therapeutics Stock vs. The Competition

TypeMiNK TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside153.04% Upside15,713.62% Upside10.24% Upside
News Sentiment Rating
Neutral News

See Recent INKT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/18/2025Zacks Research
0 of 5 stars
 DowngradeHold ➝ Strong Sell
8/15/2025HC Wainwright
1 of 5 stars
Emily Bodnar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$35.00 ➝ $35.00+128.46%
7/18/2025B. Riley
2 of 5 stars
 UpgradeStrong-Buy
7/11/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
11/15/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$80.00 ➝ $40.00+433.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:06 PM ET.


INKT Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for MiNK Therapeutics is $37.50, with a high forecast of $40.00 and a low forecast of $35.00.

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last twelve months. There is currently 1 sell rating, 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" INKT shares.

According to analysts, MiNK Therapeutics's stock has a predicted upside of 153.04% based on their 12-month stock forecasts.

Over the previous 90 days, MiNK Therapeutics's stock had 3 downgrades and 2 upgrades by analysts.

MiNK Therapeutics has been rated by research analysts at B. Riley, HC Wainwright, William Blair, and Zacks Research in the past 90 days.

Analysts like MiNK Therapeutics less than other "medical" companies. The consensus rating score for MiNK Therapeutics is 2.60 while the average consensus rating score for "medical" companies is 2.78. Learn more on how INKT compares to other companies.


This page (NASDAQ:INKT) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners